NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. Ten of our biosimilar products are being co-developed in collaboration with Serum Institute of India. NeuClone is also developing an additional range of biosimilars independently.
The development stage of the first five products with Serum Institute is outlined below.
ORIGINATOR
Herceptin®
Trastuzumab
Stelara®
Ustekinumab
Prolia/XGEVA®
Denosumab
Synagis®
Palivizumab
Humira®
Adalimumab
EARLY PRECLINICAL
LATE PRECLINICAL
PROCESS SCALE-UP
PHASE I
2019
PHASE III
15 other products in development.
Herceptin
Trastuzumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2018
Stelara
Ustekinumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2019
Prolia/XGEVA
Denosumab
Early Preclinical
Late Preclinical
Phase 1 – 2019
Synagis
Palivizumab
Early Preclinical
Late Preclinical
Humira
Adalimumab
Early Preclinical
Late Preclinical
